News

The first bioactive compounds were formatted and shipped to our partner sites for COVID-19 related research projects.

The EU-OPENSCREEN compound management team is back in the lab to prepare the bioactive library. The bioactive compounds are needed for COVID-19 research at our screening partner sites.

In response to the SARS-Cov2 pandemic, the Drug Discovery unit of G-INCPM in the Weizmann Institute of Science in Israel, a candidate partner site of EU-OPENSCREEN, underwent significant…

EU-OPENSCREEN is a partner in the recently submitted EUROCOVID “EUROpean COoperation for anti-VIral Drug discovery and preparedness for current and emerging coronavirus outbreaks” Horizon 2020…

Our Czech partner site, the Institute of Molecular Genetics (IMG), located in Prague, Czech Republic initiated together with other Czech academic institutions the Coronatest-hackathon initiative. The…

The “Communication Toolkit for European Research Infrastructures” provides an easy and useful set of tools, guidelines and resources to improve the communication strategy and activities of research…

Have you ever heard about High-Throughput Screening (HTS)? What is it used for? Is there any connection between HTS and drug discovery? Are there any research institutions where you can get trained in…

Our partner site Fraunhofer IME will play a key role in the EU funded consortium Exscalate4CoV (E4C) to counter the coronavirus pandemic. Fraunhofer IME will be providing the key link between…

EU-OPENSCREEN director, Wolfgang Fecke, has been elected to the ERIC Forum Executive Board as representative of the Life Science Cluster. The Executive Board is an important part of the permanent…

Do not miss to read the now publicly available article on "Accelerating Chemical Tool Discovery by Academic Collaborative Models" written by Bahne Stechmann and Wolfgang Fecke.